Zacks Investment Research upgraded shares of Celsion (NASDAQ:CLSN) from a sell rating to a hold rating in a report issued on Friday.

According to Zacks, “Celsion is dedicated to the development and commercialization of oncology drugs including tumor-targeting treatments using focused heat energy in combination with heat activated drug delivery systems. Celsion has research, license or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong, North Shore Long Island Jewish Health System. “

Shares of Celsion stock remained flat at $$2.85 on Friday. 114,849 shares of the stock were exchanged, compared to its average volume of 208,723. Celsion has a 12 month low of $1.26 and a 12 month high of $6.06. The company has a debt-to-equity ratio of 0.48, a quick ratio of 4.23 and a current ratio of 4.23. The company has a market cap of $50.58 million, a P/E ratio of -1.19 and a beta of 1.14.

Celsion (NASDAQ:CLSN) last issued its quarterly earnings results on Tuesday, August 14th. The biotechnology company reported ($0.46) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.27) by ($0.19). Celsion had a negative return on equity of 109.99% and a negative net margin of 4,479.42%. The firm had revenue of $0.13 million for the quarter, compared to the consensus estimate of $0.13 million. equities analysts predict that Celsion will post -1.56 earnings per share for the current year.

An institutional investor recently bought a new position in Celsion stock. Sabby Management LLC purchased a new position in shares of Celsion Co. (NASDAQ:CLSN) in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 369,860 shares of the biotechnology company’s stock, valued at approximately $828,000. Sabby Management LLC owned 2.08% of Celsion at the end of the most recent quarter. Hedge funds and other institutional investors own 4.82% of the company’s stock.

Celsion Company Profile

Celsion Corporation, a development stage oncology drug company, focuses on the development and commercialization of directed chemotherapy, DNA-mediated immunotherapy, and RNA based therapy products for the treatment of cancer. The company's lead product includes ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trials for primary liver cancer; and under Phase II clinical trials to treat recurrent chest wall breast cancer.

Featured Story: How Do You Make Money With Penny Stocks?

Get a free copy of the Zacks research report on Celsion (CLSN)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with's FREE daily email newsletter.